Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
Verdict at a Glance Melanotan-1 for regulated medical photoprotection with established safety data
Diabetes Care 41(8):18011808
8.2 Lactation Risk Summary There is no information regarding the presence of lixisenatide and insulin glargine in human milk, the effects on the breastfed infant, or the effects on milk production
The one whos rewriting the narrative of aging, menopause, and strength